Abstract
<abstract><p>Cancer remains a major health concern worldwide, causing high rates of morbidity and mortality. Although chemotherapy with antitumor drugs is the most common treatment for cancer, certain disadvantages limit its usage, such as the damage caused to healthy cells, side effects, and toxicity. Owing to their geometric and mechanical properties, nanotubes are promising nanocarriers of anticancer drugs. Here, the interaction energies of the encapsulation of an anticancer drug by single-walled nanotubes were calculated through the application of the 6–12 Lennard-Jones function with a continuous approach. In particular, the interaction energies of the 5-fluorouracil drug entering three different nanotubes (carbon, silicon and boron nitride) and the offset equilibria inside the nanotubes were obtained. This study aimed at determining the appropriate type and favorable size of nanotubes that can be used to encapsulate the 5-fluorouracil drug. The results showed that the optimal radii of nanotubes for encapsulating the 5-fluorouracil drug were approximately 6.08, 6.05 and 5.98 Å for carbon, boron nitride and silicon nanotubes, corresponding to -16.55, -18.20 and -17.81 kcal/mol, respectively.</p></abstract>
Publisher
American Institute of Mathematical Sciences (AIMS)
Reference28 articles.
1. M. Z. Dehaghani, F. Yousefi, S. M. Sajadi, M. T. Munir, O. Abida, S. Habibzadeh, et al., Theoretical encapsulation of fluorouracil (5-FU) anti-cancer chemotherapy drug into carbon nanotubes (CNT) and boron nitride nanotubes (BNNT), Molecules, 26 (2021), 4920. https://doi.org/10.3390/molecules26164920
2. M. Belcastro, T. Marino, T. Mineva, N. Russo, E. Sicilia, M. Toscano, Density functional theory as a tool for the prediction of the properties in molecules with biological and pharmacological significance, Theo. Comput. Chem., 4 (1996), 743–772. https://doi.org/10.1016/S1380-7323(96)80102-6
3. A. Shah, W. MacDonald, J. Goldie, 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules, Cancer Treat. Rep., 69 (1985), 739–742.
4. G. A. Caballero, R. K. Ausma, E. J. Quebbema, Longterm, ambulatory, continuous infusion of 5-FU for the treatment of advanced adenocarcinoma, Cancer Treat. Rev., 69 (1985), 13–16.
5. H. Mizutani, S. Oikawa, Y. Hiraku, M. Murata, M. Kojima, S. Kawanishi, Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper (II) and NADPH-cytochrome P450 reductase, Cancer Sci., 94 (2003), 686–691. https://doi.org/10.1111/j.1349-7006.2003.tb01503.x